A surprise loss of 23,000 US jobs in July and softer wage growth has put resilience back in the spotlight. Healthcare giants in areas such as pharmaceuticals and medical equipment are often watched closely when the broader economy looks less certain, because demand for many treatments can remain steady. This article reveals 3 large healthcare stocks from our screener that appear well placed against this backdrop.

The three stocks highlighted below are just a sample from this theme, with the full screen surfacing 31 more large healthcare companies that share similarly compelling fundamentals and business stories. To see the broader opportunity set, head straight into the Healthcare Sector Stocks screener to identify, filter and analyze the healthcare stocks that best fit your own conviction.

Envista Holdings (NVST)

Overview: Envista Holdings is a global dental supplier that makes everything from implants and clear aligners to digital imaging systems and infection prevention products, selling into dental offices, clinics, hospitals and specialist practices across the US, China and other international markets.

Operations: Envista generates about US$1.8b in revenue from Specialty Products & Technologies and around US$1.0b from Equipment & Consumables.

Market Cap: US$4.5b

Envista Holdings may appeal to investors seeking exposure to healthcare demand that can remain relatively stable when job data looks softer, since a large portion of its business comes from recurring dental consumables and ongoing treatment needs. Recent results indicated core growth, rising margins and higher full year guidance, supported by digital dentistry products and a growing relationship with large Dental Service Organizations. At the same time, investors need to weigh risks such as Chinese procurement reforms, trade barriers and reliance on external borrowing. With analysts highlighting both potential opportunities and execution questions ahead of its 2026 Investor Day, Envista appears to be a stock where doing additional research could be important.

Envista’s mix of recurring dental consumables and digital dentistry growth has investors curious. To see how that story lines up against the numbers and key execution questions, review the analysis report for Envista Holdings

Build your own healthcare resilience shortlist

Envista Holdings and the other two stocks in this article all came from a single Simply Wall St screener, but the real edge is in tailoring the criteria to what matters most to you. Use our flexible Screener to combine filters like valuation, future growth and balance sheet strength, or tap into our curated Investing Ideas if you prefer ready-made starting points.

Fisher & Paykel Healthcare (NZSE:FPH)

Overview: Fisher & Paykel Healthcare designs and manufactures respiratory care and sleep apnea equipment used in hospitals and homes worldwide, supplying products like humidifiers, masks and high flow nasal therapy systems that support patients with breathing difficulties. The company serves both acute hospital care and ongoing homecare needs, which can keep demand relatively steady through economic ups and downs.

Operations: Fisher & Paykel Healthcare generated about NZ$2.3b in revenue from respiratory products, with sales spread across North America, Europe, Asia Pacific and other regions.

Market Cap: NZ$24.5b

Fisher & Paykel Healthcare may be relevant if you are looking at healthcare companies that sell essential equipment rather than discretionary treatments. Revenue reached NZ$2,308.4 million and net income NZ$468.5 million in the year to March 31, 2026, supported by high margins, a strong respiratory product portfolio and recurring hospital and homecare usage. That profile can be of particular interest when job data weakens and investors pay closer attention to demand that is less tied to employment cycles. At the same time, the stock trades on a high P/E multiple and faces pressure from healthcare budgets, tariffs and strong competition, so expectations are already demanding. The combination of quality, steady dividends and a rich valuation means Fisher & Paykel Healthcare is a stock where deeper research can be especially important.

Fisher & Paykel Healthcare combines high margins, global reach and a rich P/E that many investors focus on first. The real twist often sits inside the detailed analysis report for Fisher & Paykel Healthcare

Neurocrine Biosciences (NBIX)

Overview: Neurocrine Biosciences is a US based pharmaceutical company that focuses on treatments for neurological, psychiatric, endocrine and immunological disorders, with approved drugs for conditions such as tardive dyskinesia, Huntington’s disease related chorea, endometriosis, uterine fibroids and congenital adrenal hyperplasia, alongside a broad late stage central nervous system pipeline.

Operations: Neurocrine Biosciences generates about US$3.4b in revenue from researching, developing, commercializing and selling pharmaceuticals, with all reported sales coming from the United States.

Market Cap: US$16.6b

Neurocrine Biosciences may appeal if you want a larger pharmaceutical company that sits squarely in the defensive side of healthcare while still being tied to drug innovation. The core INGREZZA and CRENESSITY franchises, together with rising contributions from VYKAT XR, underpin recent quarterly revenue of about US$959 million and support the company’s own higher sales guidance. At the same time, reliance on a handful of key products, growing payer scrutiny and pricing pressure, and the cost of a busy late stage pipeline mean execution risk is real. With analysts seeing considerable value in future cash flows, the real question is how comfortable you are with those assumptions in light of concentrated products and a crowded neuroscience field.

Neurocrine Biosciences sits at the crossroads of established franchises and a busy late stage pipeline, yet the real story is how expectations stack up against execution. See how the market’s assumptions compare with the analyst forecasts for Neurocrine Biosciences

Seeking Alternatives Before Momentum Flies Past

Fresh stock ideas can move from quiet to breakout faster than most investors react. Some of the best setups get caught early and drift away under the radar for now, so investors may want to research potential opportunities promptly.

• Scan the curated 51 high quality undervalued stocks to research potential early-stage turnarounds before momentum becomes widely recognized, while much of the market is still focused on prior leaders.
• Monitor the targeted 55 AI infrastructure stocks to follow companies involved in digital infrastructure as these themes develop over time.
• Review the focused 30 elite gold producer stocks to stay informed on potential changes in commodity sentiment while many investors may not be paying close attention to precious metals producers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.